Protein Quality Control Network

Protein Quality Control Network

The protein quality control (PQC) network is the cell's comprehensive defense system against proteotoxic stress, comprising interconnected pathways that maintain proteostasis. This network encompasses molecular chaperones, the ubiquitin-proteasome system (UPS), autophagy-lysosomal pathways, the unfolded protein response (UPR), and ER-associated degradation (ERAD). Failure of these systems is a central mechanism in neurodegenerative diseases, where misfolded proteins accumulate as toxic aggregates.

Pathway Diagram

Molecular Components

1. Molecular Chaperones

Molecular chaperones are proteins that assist in proper protein folding and prevent aggregation. The major chaperone systems include:

Protein Quality Control Network

The protein quality control (PQC) network is the cell's comprehensive defense system against proteotoxic stress, comprising interconnected pathways that maintain proteostasis. This network encompasses molecular chaperones, the ubiquitin-proteasome system (UPS), autophagy-lysosomal pathways, the unfolded protein response (UPR), and ER-associated degradation (ERAD). Failure of these systems is a central mechanism in neurodegenerative diseases, where misfolded proteins accumulate as toxic aggregates.

Pathway Diagram

Molecular Components

1. Molecular Chaperones

Molecular chaperones are proteins that assist in proper protein folding and prevent aggregation. The major chaperone systems include:

| Chaperone | Type | Function | Disease Relevance |
|-----------|------|----------|-------------------|
| HSP70 | ATP-dependent | Folding, disaggregation | AD, PD, HD |
| HSP90 | ATP-dependent | Folding, stability | ALS, cancer |
| HSC70 | ATP-dependent | Co-chaperone, ERAD | PD, ALS |
| BiP/GRP78 | HSP70 family | ER chaperone, UPR regulation | AD, PD |
| DNAJ/HSP40 | Co-chaperone | HSP70 recruitment | HD |

References: [@hartl2011], [@kim2022], [@ciechanover2015]

2. Ubiquitin-Proteasome System (UPS)

The UPS is the primary pathway for targeted protein degradation: [@nixon2013]

• Ubiquitination: E1 (activating), E2 (conjugating), E3 (ligase) enzymes tag proteins with ubiquitin
• 26S Proteasome: Recognizes polyubiquitinated proteins, unfolds them, and degrades to peptides
• Linkage Types: K48 (proteasomal), K63 (autophagic/lysosomal), K27 (ERAD)

3. Autophagy-Lysosomal Pathway

Autophagy degrades bulk protein aggregates and damaged organelles: [@valenti2022]

• Macroautophagy: Formation of autophagosomes that fuse with lysosomes
• Chaperone-mediated autophagy (CMA): Direct translocation of proteins across lysosomal membrane
• Microautophagy: Direct engulfment by lysosomes

4. Unfolded Protein Response (UPR)

The UPR is a transcriptional response to ER stress: [@zhang2022]

| Sensor | Domain | Downstream Effect |
|--------|--------|-------------------|
| PERK | Kinase | eIF2α phosphorylation → translation attenuation |
| IRE1 | Kinase/RNase | XBP1 splicing → chaperone upregulation |
| ATF6 | Transcription factor | ATF6f cleavage → ERAD component expression |

References: [@hartl2011], [@kim2022], [@glick2010], [@fujita2007], [@senft2015]

5. ER-Associated Degradation (ERAD)

ERAD retrotranslocates misfolded proteins from the ER to the cytosol for proteasomal degradation:

• Recognition: Misfolded proteins recognized by chaperones (BiP, calnexin)
• Retrotranslocation: Sec61 translocon or Derlin complexes
• Ubiquitination: E3 ligases (HRD1, SEL1L) in cytosol
• Degradation: 26S proteasome

Disease-Specific Failures

Alzheimer's Disease (AD)

| PQC Component | Defect | Evidence |
|---------------|--------|----------|
| [UPS](/mechanisms/ubiquitin-proteasome-system) | Reduced proteasome activity | ↓20S proteasome in AD brain |
| Autophagy | Impaired lysosomal acidification | Cathepsin D deficiency in AD |
| UPR | Chronic activation → [apoptosis](/mechanisms/apoptosis) | PERK, IRE1 hyperactivated in AD |
| Chaperones | HSP70 decreased | Reduced HSP70 in temporal cortex |

Parkinson's Disease (PD)

| PQC Component | Defect | Evidence |
|---------------|--------|----------|
| Autophagy | PINK1/Parkin mitophagy failure | Loss-of-function mutations in PD |
| Proteasome | GBA1 deficiency affects | Glucocerebrosidase mutations ↑ PD risk |
| Chaperones | HSP70 compromised | DNAJC proteins mutated in PD |
| ERAD | LRRK2 affects ER export | G2019S LRRK2 disrupts ERAD |

Amyotrophic Lateral Sclerosis (ALS)

| PQC Component | Defect | Evidence |
|---------------|--------|----------|
| UPS | Ubiquitin inclusions | Bunina bodies, skein-like inclusions |
| Autophagy | p62, OPTN mutations | Autophagy receptor mutations cause ALS |
| ERAD | VCP mutations | Valosin-containing protein mutations |
| Proteostasis | C9orf72 affects | Hexanucleotide expansion disrupts |

Huntington's Disease (HD)

| PQC Component | Defect | Evidence |
|---------------|--------|----------|
| UPR | Chronic ER stress | PERK, IRE1, ATF6 dysregulated |
| Autophagy | mTOR hyperactivation | Excessive autophagy |
| Chaperones | HTT sequesters chaperones | Mutant huntingtin traps HSP70/HSP90 |
| UPS | Impaired degradation | Ubiquitinated aggregates |

Prion Diseases

| PQC Component | Defect | Evidence |
|---------------|--------|----------|
| UPS | Overwhelmed by PrP^Sc | Proteasome inhibited |
| Autophagy | Dysregulated | Autophagosome accumulation |
| Chaperones | Failed clearance | HSP70 ineffective against prions |

Therapeutic Strategies

1. Chaperone-Based Therapies

| Strategy | Agent | Mechanism | Stage |
|----------|-------|-----------|-------|
| HSP70 inducers | Geldanamycin derivatives | Hsp90 inhibition → Hsp70 upregulation | Preclinical |
| HSP90 inhibitors | 17-DMAG, PU-DZ8 | Release HSF1 → chaperone expression | Phase I/II |
| Chemical chaperones | TUDCA, glycerol | Protein stabilization | Phase II/III |

2. Proteasome Enhancement

| Strategy | Agent | Mechanism | Stage |
|----------|-------|-----------|-------|
| Proteasome activators | PA28γ | Enhanced proteasome activity | Preclinical |
| Ubiquitination modulators | E3 ligase modulators | Increase degradation of misfolded proteins | Discovery |

3. Autophagy Modulation

| Strategy | Agent | Mechanism | Stage |
|----------|-------|-----------|-------|
| mTOR inhibitors | Rapamycin, Everolimus | Autophagy induction | Approved |
| mTOR-independent | Trehalose, lithium | TFEB activation | Phase II |
| TFEB activators | AAV-TFEB | Lysosomal biogenesis | Preclinical |

4. UPR Modulation

| Strategy | Agent | Mechanism | Stage |
|----------|-------|-----------|-------|
| PERK inhibitors | GSK2656157 | Prevent eIF2α hyperphosphorylation | Preclinical |
| IRE1 inhibitors | MKC8866 | Reduce XBP1 splicing | Preclinical |
| BiP inducers | TUDCA | ER chaperone upregulation | Phase II |

Cross-Links to Related Pathways

• Amyloid Cascade Pathway — Aβ overwhelms PQC
• Alpha-Synuclein Aggregation Pathway — α-syn evades PQC
• Tau Pathology Pathway — Tau oligomers trigger UPR
• Mitochondrial Dysfunction Pathway — Mitochondrial protein import overlaps with ERAD
• Neuroinflammation Pathway — PQC failure activates microglia

Cross-Links to Entity Pages

• HSP70 — Major molecular chaperone
• HSP90 — HSP90 client proteins
• Ubiquitin — UPS tag molecule
• p62/SQSTM1 — Autophagy receptor
• XBP1 — UPR transcription factor

References

See Also

• [Mechanisms Index](/mechanisms)
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosome-neurodegeneration)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• Ubiquitin-Proteasome System

Confidence Assessment

🟡 Moderate Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 19 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |

Overall Confidence: 42%